Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer | Zendy

Yutaka Ogata | Zendy; Takaho Tanaka | Zendy; Yoshito Akagi | Zendy; Nobuya Ishibashi | Zendy; Yoshiaki Tsuji | Zendy; Keiko Matono | Zendy; Makoto ISOBE | Zendy; Susumu Sueyoshi | Zendy; Atsushi Kaibara | Zendy; Kazuo Shirouzu | Zendy

Open Access

Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer

Author(s) -

Yutaka Ogata,

Takaho Tanaka,

Yoshito Akagi,

Nobuya Ishibashi,

Yoshiaki Tsuji,

Keiko Matono,

Makoto ISOBE,

Susumu Sueyoshi,

Atsushi Kaibara,

Kazuo Shirouzu

Publication year - 2013

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s10769

Subject(s) - medicine , irinotecan , folfiri , regimen , neutropenia , colorectal cancer , anemia , phases of clinical research , chemotherapy , oncology , tegafur , febrile neutropenia , gastroenterology , cancer

This multicenter phase II study determined the efficacy and safety of new daily oral S-1 and weekly irinotecan (CPT-11) combination schedule in patients with previously untreated advanced or recurrent colorectal cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research